Browse News
Filter News
Found 13,861 articles
-
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
4/18/2024
AtriCure, Inc. announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device.
-
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
4/18/2024
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
4/18/2024
NRx Pharmaceuticals, Inc. announced that has received confirmation from Nasdaq that they have demonstrated compliance with the Nasdaq bid price requirement in Listing Rule 5550 and has determined to continue the listing of the Company's securities on The Nasdaq Stock Market and is closing this matter.
-
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
4/18/2024
NRx Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of shares of its common stock at a public offering price of $3.30 per share, for aggregate gross proceeds of approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
4/17/2024
NRx Pharmaceuticals today announced new data that demonstrate that in a rodent model NRX-101 shows no measurable damage to either intestinal or vaginal flora, compared to the significant negative effect caused by drugs such as ciprofloxacin.
-
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock - April 17, 2024
4/17/2024
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
-
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
4/17/2024
Orexo AB, announces that the United States Patent and Trademark Office has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
-
Alkermes to Report First Quarter Financial Results on May 1, 2024
4/17/2024
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to discuss the company's first quarter financial results.
-
Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
4/16/2024
Jaguar Health, Inc. today announced that it has signed an exclusive 5-year in-license agreement with United Kingdom-based Venture Life Group PLC.
-
Autonomix Announces Issuance of U.S. Patent Covering Proprietary Catheter-Based Technology for the Treatment of Cancer Related Pain
4/16/2024
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent 10,143,419 ('419 patent) entitled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function.”
-
Antibe Announces TSX Delisting Review
4/16/2024
Antibe Therapeutics Inc. announced that the Toronto Stock Exchange is reviewing the eligibility for continued listing on the TSX of the securities of the Company.
-
Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile
4/16/2024
Masimo announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety.
-
Following cases of convulsions in rabbits in a preclinical study, the FDA has placed a clinical hold on Neumora Therapeutics’ Phase I schizophrenia drug candidate NMRA-266.
-
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
4/15/2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that the Company has developed a novel, proprietary formulation of IV Ketamine for use as HTX-100.
-
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study
4/15/2024
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
4/12/2024
Eisai Inc. announced today the Company will present findings from its robust neurology portfolio, including data from the Phase 3 Clarity AD trial for LEQEMBI ® .
-
NEURELIS ANNOUNCES TWO POSTER PRESENTATIONS AT THE 76TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY
4/11/2024
Neurelis, Inc. will present a poster on VALTOCO® (diazepam nasal spray) for the treatment of episodes of frequent seizure activity (i.e., seizure clusters) in patients with epilepsy ages 6 to 65 years, describing the time to treatment across different subpopulations.
-
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
4/11/2024
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.